Tweet
Aridis Pharmaceuticals is buying Kenta Biotech’s anti-infection treatment products for an undisclosed amount. The acquisition includes six products to treat infections, such as skin infections or respiratory infections, caused by common pathogens. Aridis is also buying a technology that helps discover naturally occurring protective antibodies generated by the human immune system. Terms of the deal were not disclosed. Aridis, headquartered in San Jose, Calif., focuses on developing anti-infective drugs to treat lung infections and other infections. Zurich-based Kenta also develops medications to treat infections. Other recent pharmaceutical deals include Takeda Pharmaceutical Co. Ltd.’s purchase of Inviragen , Auxilium Pharmaceuticals Inc.’s (Nasdaq: AUXL) Actient Holdings LLC  and Opko Health Inc.’s (NYSE: OPK) acquisition of Prolor Biotech Inc. (NYSE: PBTH).

Aridis Pharma Picks Up Kenta Biotech's Anti-Infection Products

Kenta Biotech
SAN JOSE, Calif., May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce that an agreement has been reached with Switzerland-based Kenta Biotech to acquire Kenta's entire portfolio of anti-infective human monoclonal antibody (mAb) products, and technologies. This asset portfolio purchase includes six anti-infective human mAb products for treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). This acquisition comprises an impressive portfolio of mAb products which includes two candidates in phase 2a clinical trials for acute pneumonia. Aridis Founder & President Eric Patzer stated; "We are pleased to complete this transaction and build upon the substantial financial investment and remarkable progress that our colleagues at Kenta Biotech have achieved in creating a portfolio of innovative products". Kenta CEO Franco Merckling added: "We are pleased to have identified Aridis as the ideal partner to further develop the Kenta technology and project pipeline which has been built over the last seven years. Aridis, a leadingSan Francisco area biotech company specializing in novel anti-infectives, is poised to accelerate the development of our drug candidates in both the US and Europe". Accompanying the mAb products is an antibody discovery platform that enables the recovery of very rare, naturally occurring protective antibodies generated by the human immune system (called 'MabIgx' technology). This technology platform also enables rapid development of natural human antibodies into medicines. "Combined with Aridis' anti-infective product portfolio, this acquisition clearly places Aridis in a leadership position in anti-infective mAbs. This promising new class of anti-infectives presents very significant advantages over conventional antibiotics that are prone to drug resistance' said Aridis Founder & Chief Scientific Officer Dr. Vu Truong. This portfolio of mAb products will be folded into Aridis' Switzerland subsidiary to facilitate completion of the ongoing clinical trial and provide access to an excellent range of resources in Switzerland. Our current financing activities will fund the completion of the on-going phase 2a clinical trial in pneumonia patients infected with antibiotic resistant strains of S. aureus (e.g. MRSA, MSSA), and also to advance two additional IND stage products through phase 1 clinical testing. These clinical trials will be completed within 18-24 months. About Aridis
Aridis Pharmaceuticals is a privately held biopharmaceutical company headquartered in San Jose, CA, with a subsidiary in Switzerland. The Company is focused on the development of novel anti-infective drugs for the treatment of lung infections and other surface infections. Our products target infectious diseases that have a significant impact on life expectancy and address acute unmet medical needs including: nosocomial infections [Hospital acquired pneumonia, ventilator associated pneumonia], lung infections associated with cystic fibrosis, and severe wound infections. Aridis has a best-in-class anti-infective monoclonal antibody which targets P. aeruginosa (AerucinTM). Complementing the mAbs is a broad spectrum anti-infective, gallium citrate (PanaecinTM), which has shown preliminary efficacy and safety in a human clinical trial. The Company is a recognized global leader in biopharmaceutical stabilization formulation technologies and has successfully attained over $20m in non-dilutive funding. www.aridispharma.com  
About Kenta Biotech
Kenta Biotech is a biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland, focused on the development of innovative fully human monoclonal antibodies for the prevention and treatment of life-threatening infections. Kenta harnesses the power of the human immune system for the generation of fully human monoclonal antibodies and their transformation into highly effective therapeutic antibodies. This unique technology enables Kenta Biotech to move innovative antibody therapies rapidly from the bench to high medical need patients. Several product candidates are in clinical phase 2a and preclinical development. www.kentabiotech.com
Further information, please contact:

Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech

Kenta Biotech

Eisai

Merck & Co.

Eli Lilly and Company

Lilly Diabetes

Kenta Biotech is focusing on the discovery and development of fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.

Viventia Bio Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Updated: 19122016] Prices from USD $250
19:05 EST 26 Jan 2017 | BioPortfolio Reports
Home » Topics » Biotechnology » Latest News » Viventia Bio Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Updated: 19122016] Prices from USD $250
Summary
Viventia Bio Inc Viventia Bio, formerly Viventia Biotechnologies Inc. is a biopharmaceutical company that discovers and develops new generation monoclonal antibody products for patients suffering from cancer. The company's products include VB4845, VB4847, VB6845d and VB7756. Its VB4845 is a recombinant fusion protein, which is designed for the treatment of highgrade nonmuscle invasive bladder cancer. Viventia Bio's VB4847 is a recombinant fusion protein, which is designed for the treatment of latestage squamous cell carcinoma of the head and neck. The company provides immune driven antibody platform to select tumorspecific antibodies with no to minimal normal tissue reactivity using functional assays. Viventia is headquartered in Winnipeg, Manitoba, Canada. Viventia Bio Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News


Viventia Bio Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Updated 19122016 Prices from USD $250

Viventia Bio Inc.  Pharmaceuticals  Healthcare  Deals and Alliances Profile Prices from USD $250
23:26 EST 23 Nov 2016 | BioPortfolio Reports
Home » Topics » Biotechnology » Latest News » Viventia Bio Inc.  Pharmaceuticals  Healthcare  Deals and Alliances Profile Prices from USD $250
Summary
Viventia Bio Inc. Viventia Bio,formerly Viventia Biotechnologies Inc. is a biopharmaceutical company that discovers and develops new generation monoclonal antibody products for patients suffering from cancer. The company's products include VB4845, VB4847, VB6845d and VB7756. Its VB4845 is a recombinant fusion protein, which is designed for the treatment of highgrade nonmuscle invasive bladder cancer. Viventia Bio's VB4847 is a recombinant fusion protein, which is designed for the treatment of latestage squamous cell carcinoma of the head and neck. The company provides immune driven antibody platform to select tumorspecific antibodies with no to minimal normal tissue reactivity using functional assays. Viventia is headquartered in Winnipeg, Manitoba, Canada. Viventia Bio Inc.  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News


Viventia Bio Inc.  Pharmaceuticals  Healthcare  Deals and Alliances Profile Prices from USD $250

Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted      Protein Therapeutics Oncology Company
-Viventia’s Lead Product Candidate, ViciniumTM,      being developed for high-grade non-muscle invasive bladder cancer, with      topline Phase 3 data expected in 1H 2018-
-ProxiniumTM being developed for late-stage      squamous cell carcinoma of the head and neck with Phase 2 initiation      planned for early 2017-
-Stephen Hurly to Serve as President and Chief Executive Officer of      Combined Company-
-Company to Host Conference Call and Webcast Today September 21, 2016      at 8:30 AM ET-
September 21, 2016 07:00 AM Eastern Daylight Time
CAMBRIDGE, Mass. & TORONTO--( BUSINESS WIRE )--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today      announced that the two companies and the shareholders of Viventia      entered into a definitive share purchase agreement under which Eleven      Biotherapeutics agreed to, and simultaneously completed, the acquisition      of Viventia. Under the agreement, Eleven purchased all of the      outstanding capital stock of Viventia in exchange for the issuance of      4,013,431 newly issued shares of Eleven common stock, which represented      approximately 19.9% of the voting power of Eleven as of immediately      prior to the issuance of such shares, and the agreement by Eleven to pay      to the selling shareholders certain post-closing contingent cash      payments upon the achievement of specified milestones and based upon net      sales related to Viventia’s lead product candidate, Vicinium. The acquisition creates a NASDAQ-listed company focused on the      development of novel therapies based upon antibody fragments genetically      fused to cytotoxic proteins, or targeted protein therapeutics (TPTs), as      new treatments in areas of oncology with significant unmet need. The      combined company will continue to be named Eleven Biotherapeutics, and      Stephen Hurly, formerly Viventia’s chief executive officer, was      appointed President and Chief Executive Officer of Eleven in connection      with the acquisition. Abbie C. Celniker, Eleven’s former President and      Chief Executive Officer, will remain a director of Eleven      Biotherapeutics. Eleven’s pipeline now includes Viventia’s lead product candidates      Vicinium and Proxinium. Vicinium is in a Phase 3 clinical trial for high      grade non-muscle invasive bladder cancer (NMIBC), with topline data      expected in the first half of 2018. To date, Vicinium has been evaluated      in more than 100 patients. In a Phase 2 clinical trial, Vicinium      demonstrated a complete response rate of 40% at three months with no      drug-related serious adverse events observed in the trial. Proxinium is expected to enter Phase 2 development in early 2017 for the      treatment of late-stage squamous cell carcinoma of the head and neck. In      previous clinical trials, Proxinium was generally safe and      well-tolerated and showed signs of anti-tumor activity. Proxinium has      received Orphan Drug Designation from the U.S. Food and Drug      Administration (FDA) and the European Medicines Agency (EMA), and Fast      Track designation from the FDA. Both product candidates are anti-EpCAM      (epithelial cell adhesion molecule) fusion proteins that have been      optimized for local tumor administration. Eleven’s pipeline now also includes Viventia’s earlier stage pipeline of      next generation TPT candidates that are designed and optimized for      systemic administration for the potential treatment of a broader      spectrum of cancer types. “We are excited to join with Eleven to create a company with extensive      experience in engineering and developing novel protein therapeutics for      local delivery that we believe may maximize efficacy and reduce      toxicity. Our TPTs combine specific tumor targeting with a protein based      tumor killing payload, and will be developed to serve cancer patients in      areas of high unmet need. Together we have a strong Board of Directors,      management team, product pipeline and technology platform, and the      capital needed to support the Company’s development plans into 2018,”      said Stephen Hurly, Chief Executive Officer of Eleven Biotherapeutics. “As previously announced, Eleven performed an extensive review of our      strategic alternatives, and our Board of Directors believes that the      acquisition of Viventia offers Eleven shareholders a compelling      opportunity for enhancing long-term value,” said Abbie Celniker, Ph.D.,      former President and Chief Executive Officer of Eleven Biotherapeutics      and current member of Eleven’s Board of Directors. “Our combined company      will continue to support Roche as they develop EBI-031, and will benefit      from the capital contributed by this partnership, which provides the      necessary funding to enable further development of Vicinium and      Proxinium.”
About Targeted Protein Therapeutics (TPTs)
Viventia’s drug development is currently focused on locally administered      targeted protein therapeutics (TPTs) for the treatment of cancer. Viventia’s TPTs are expressed as a single fusion protein with a      differentiated payload mechanism, eliminating the need for payload      conjugation and multi-step manufacturing. We believe TPTs have a dual      action of both directly killing the cancer cell and enhancing the local      immune response. License Agreement with Roche
On August 16, 2016, Eleven announced the effectiveness of its exclusive      license agreement with F. Hoffman-La Roche Ltd. and Hoffman-La Roche      Inc. (Roche) for Eleven’s IL-6 antagonist antibody technology, including      EBI-031. Eleven granted Roche an exclusive, worldwide license to develop      and commercialize EBI-031 and all other IL-6 antagonist antibody      technology owned by Eleven. Eleven has received $30 million in payments      from Roche, including a $7.5 million upfront payment in connection with      the effectiveness of the license agreement, and a $22.5 million      milestone payment based on the Investigational New Drug (IND)      application for EBI-031 becoming effective. Under the terms of the      agreement, Eleven could receive up to an additional $240 million upon      the achievement of certain future regulatory, development and      commercialization milestones. In addition, Eleven could be entitled to      receive royalties based on net sales of potential future products      containing EBI-031 or any other potential future products containing      other Eleven IL-6 compounds. Viventia Acquisition Details
Under the share purchase agreement, Eleven purchased all of the      outstanding capital stock of Viventia in exchange for the issuance of      4,031,431 newly issued shares of Eleven common stock, which represented      approximately 19.9% of the voting power of Eleven as of immediately prior to the issuance of such shares, and the agreement by Eleven to pay      to the selling shareholders certain post-closing contingent cash      payments upon the achievement of specified milestones and based upon net      sales related to Viventia’s lead product candidate, Vicinium. The acquisition was approved by the boards of directors of both      companies. Stifel, Nicolaus & Company, Incorporated acted as financial advisor and      Wilmer Cutler Pickering Hale and Dorr LLP is acting as legal advisor to      Eleven. Hogan Lovells US LLP acted as legal counsel to Viventia. Management and Organization
In connection with the acquisition, Eleven’s Board of Directors elected      Stephen Hurly and Leslie L. Dan, Viventia’s former Executive Chairman      and largest beneficial owner prior to the acquisition, to serve as      members of Eleven’s Board of Directors, and Cary G. Pfeffer, M.D.,      resigned from the Eleven’s Board of Directors. Stephen Hurly will serve      as President and Chief Executive Officer of Eleven. Also in connection      with the acquisition, Arthur P. DeCillis, M.D., Viventia’s Chief Medical      Officer, was appointed as Chief Medical Officer of Eleven, and Karen L.      Turbidy, Eleven’s Chief Development Officer, resigned from Eleven. In      addition, Gregory Adams Ph.D., Chief Development Officer and Glen      MacDonald, Ph.D., Chief Scientific Officer, will join Eleven’s      management team from Viventia. John McCabe, will continue to serve as      Chief Financial Officer of Eleven. Abbie C. Celniker, former President      and Chief Executive Officer of Eleven, will remain a member of Eleven’s      Board of Directors. Following the acquisition, an entity affiliated with      Leslie L. Dan became the second largest shareholder of Eleven. Conference Call and Webcast
Eleven Biotherapeutics and Viventia will host a conference call and      audio webcast today at 8:30 a.m. ET to discuss the acquisition. To      access the conference call, please dial (844) 831-3025 (domestic) or      (315) 625-6887 (international) at least five minutes prior to the start      time and refer to conference ID 85062695. An audio webcast of the call will also be available on the Investors & Media section of the Company's website,  www.elevenbio.com . An archived webcast will be available on the Company's website      approximately two hours after the event and will be available for 30      days. About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing      a broad pipeline of novel anti-cancer agents based on the Company's      targeted protein therapeutics (TPTs) platform. The Company's TPTs      genetically combine antibody-based fragments with protein immunotoxin      payloads to create a single protein molecule through the Company's      proprietary one-step manufacturing process. The Company believes its      TPTs can potentially offer significant advantages in treating cancer      versus existing antibody drug conjugate technologies. The Company’s      approach to drug design creates TPTs that it believes facilitate      effective tumor targeting with cancer cell-killing properties unique to      protein payloads versus small molecules. The ability of TPTs cancer      cell-killing properties to promote an anti-tumor immune response suggest      that TPTs will potentially combine well with immune oncology drugs. TPTs      fusion protein construction provides enhanced linker stability and an      efficient and cost effective manufacturing process. For more information      please refer to the Company’s website www.elevenbio.com . About Non-Muscle Invasive Bladder Cancer (NMIBC)
In the U.S., NMIBC is the second most common malignancy of the      genitourinary system, accounting for 70% to 80% of all bladder cancers,      and is the sixth most common cancer diagnosed worldwide. The American      Cancer Society estimated that approximately 74,000 new cases of bladder      cancer were diagnosed in 2015 and that this cancer caused approximately      16,000 deaths in the US in 2015. NMIBC is highly recurrent and requires      ongoing, invasive monitoring. The standard immunotherapy drug for bladder cancer is the Bacillus      Calmette-Guérin (BCG) vaccine which was approved by the U.S. Food and      Drug Administration (FDA) to treat NMIBC carcinoma in situ in 1990. As a      front-line therapy, BCG, with or without transurethral resection of the      bladder tumor (TURBT) is associated with high failure rates: 50% of      patients experience disease recurrence within one year and 90% relapse      within five years. For more information please visit www.mybladdercancer.com . About Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Squamous cell carcinoma is the most frequent malignant tumor of the head      and neck region. Head and neck cancer is the seventh most common cancer      in the world. Head and neck cancers are strongly associated with certain      environmental and lifestyle risk factors. Existing treatment options for squamous cell carcinoma of the head and      neck include surgery, drug agents, radiation or combination therapy. There is no treatment option for patients who progress after receiving      these treatments. Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans      and prospects for the Company, including statements about benefits of      the Acquisition, future management of the Company, Viventia’s business,      the Company's strategy, future operations, advancement or maturation of      its product candidates and product pipeline, clinical development of the      Company's product candidates, including expectations regarding timing of      regulatory submissions and initiation of clinical trials, regulatory      requirements for initiation of clinical trials and registration of      product candidates, the sufficiency of its cash resources and other      statements containing the words "anticipate," "believe," "estimate,"      "expect," "intend," "may," "plan," "predict," "project," "target,"      "potential," "will," "would," "could," "should," "continue," and similar      expressions, constitute forward-looking statements within the meaning of      The Private Securities Litigation Reform Act of 1995. Actual results may      differ materially from those indicated by such forward-looking      statements as a result of various important factors, including: the      uncertainties inherent in the initiation and conduct of clinical trials,      availability and timing of data from clinical trials, whether results of      early clinical trials or preclinical studies will be indicative of the      results of future trials, the adequacy of any clinical models,      uncertainties associated with regulatory review of clinical trials and      applications for marketing approvals and other factors discussed in the      "Risk Factors" section of the Company's report on Form 10-Q for the quarter ended June 30, 2016 as filed with the Securities and Exchange      Commission, the “Risk Factors of Viventia’s Business” filed as Exhibit      99.2 to the Company’s Current Report on Form 8-K filed with the      Securities and Exchange Commission on September 21, 2016 and other      reports on file with the Securities and Exchange Commission. In      addition, the forward-looking statements included in this press release      represent the Company's views as of the date hereof. The Company      anticipates that subsequent events and developments will cause the      Company's views to change. However, while the Company may elect to      update these forward-looking statements at some point in the future, the      Company specifically disclaims any obligation to do so. These      forward-looking statements should not be relied upon as representing the      Company's views as of any date subsequent to the date hereof. Contacts

Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company

Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
Posted: September 21, 2016 11:55 am (UTC)
print
Tweet
Creates a NASDAQ-listed company focused on the development of targeted protein therapeutics (TPTs), as new treatments in areas of oncology with significant unmet need
-Viventia’s Lead Product Candidate, ViciniumTM,        being developed for high-grade non-muscle invasive bladder cancer, with        topline Phase 3 data expected in 1H 2018-
-ProxiniumTM being developed for late-stage        squamous cell carcinoma of the head and neck with Phase 2 initiation        planned for early 2017-
-Stephen Hurly to Serve as President and Chief Executive Officer of        Combined Company-
-Company to Host Conference Call and Webcast Today September 21, 2016        at 8:30 AM ET-
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted        Protein Therapeutics Oncology Company
CAMBRIDGE, Mass. & TORONTO — (BUSINESS WIRE) —
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today        announced that the two companies and the shareholders of Viventia        entered into a definitive share purchase agreement under which Eleven        Biotherapeutics agreed to, and simultaneously completed, the acquisition        of Viventia. Under the agreement, Eleven purchased all of the        outstanding capital stock of Viventia in exchange for the issuance of        4,013,431 newly issued shares of Eleven common stock, which represented        approximately 19.9% of the voting power of Eleven as of immediately        prior to the issuance of such shares, and the agreement by Eleven to pay        to the selling shareholders certain post-closing contingent cash        payments upon the achievement of specified milestones and based upon net        sales related to Viventia’s lead product candidate, Vicinium. The acquisition creates a NASDAQ-listed company focused on the        development of novel therapies based upon antibody fragments genetically        fused to cytotoxic proteins, or targeted protein therapeutics (TPTs), as        new treatments in areas of oncology with significant unmet need. The        combined company will continue to be named Eleven Biotherapeutics, and        Stephen Hurly, formerly Viventia’s chief executive officer, was        appointed President and Chief Executive Officer of Eleven in connection        with the acquisition. Abbie C. Celniker, Eleven’s former President and        Chief Executive Officer, will remain a director of Eleven        Biotherapeutics. Eleven’s pipeline now includes Viventia’s lead product candidates        Vicinium and Proxinium. Vicinium is in a Phase 3 clinical trial for high        grade non-muscle invasive bladder cancer (NMIBC), with topline data        expected in the first half of 2018. To date, Vicinium has been evaluated        in more than 100 patients. In a Phase 2 clinical trial, Vicinium        demonstrated a complete response rate of 40% at three months with no        drug-related serious adverse events observed in the trial. Proxinium is expected to enter Phase 2 development in early 2017 for the        treatment of late-stage squamous cell carcinoma of the head and neck. In        previous clinical trials, Proxinium was generally safe and        well-tolerated and showed signs of anti-tumor activity. Proxinium has        received Orphan Drug Designation from the U.S. Food and Drug        Administration (FDA) and the European Medicines Agency (EMA), and Fast        Track designation from the FDA. Both product candidates are anti-EpCAM        (epithelial cell adhesion molecule) fusion proteins that have been        optimized for local tumor administration. Eleven’s pipeline now also includes Viventia’s earlier stage pipeline of        next generation TPT candidates that are designed and optimized for        systemic administration for the potential treatment of a broader        spectrum of cancer types. “We are excited to join with Eleven to create a company with extensive        experience in engineering and developing novel protein therapeutics for        local delivery that we believe may maximize efficacy and reduce        toxicity. Our TPTs combine specific tumor targeting with a protein based        tumor killing payload, and will be developed to serve cancer patients in        areas of high unmet need. Together we have a strong Board of Directors,        management team, product pipeline and technology platform, and the        capital needed to support the Company’s development plans into 2018,”        said Stephen Hurly, Chief Executive Officer of Eleven Biotherapeutics. “As previously announced, Eleven performed an extensive review of our        strategic alternatives, and our Board of Directors believes that the        acquisition of Viventia offers Eleven shareholders a compelling        opportunity for enhancing long-term value,” said Abbie Celniker, Ph.D.,        former President and Chief Executive Officer of Eleven Biotherapeutics        and current member of Eleven’s Board of Directors. “Our combined company        will continue to support Roche as they develop EBI-031, and will benefit        from the capital contributed by this partnership, which provides the        necessary funding to enable further development of Vicinium and        Proxinium.”
About Targeted Protein Therapeutics (TPTs)
Viventia’s drug development is currently focused on locally administered        targeted protein therapeutics (TPTs) for the treatment of cancer. Viventia’s TPTs are expressed as a single fusion protein with a        differentiated payload mechanism, eliminating the need for payload        conjugation and multi-step manufacturing. We believe TPTs have a dual        action of both directly killing the cancer cell and enhancing the local        immune response. License Agreement with Roche
On August 16, 2016, Eleven announced the effectiveness of its exclusive        license agreement with F. Hoffman-La Roche Ltd. and Hoffman-La Roche        Inc. (Roche) for Eleven’s IL-6 antagonist antibody technology, including        EBI-031. Eleven granted Roche an exclusive, worldwide license to develop        and commercialize EBI-031 and all other IL-6 antagonist antibody        technology owned by Eleven. Eleven has received $30 million in payments        from Roche, including a $7.5 million upfront payment in connection with        the effectiveness of the license agreement, and a $22.5 million        milestone payment based on the Investigational New Drug (IND)        application for EBI-031 becoming effective. Under the terms of the        agreement, Eleven could receive up to an additional $240 million upon        the achievement of certain future regulatory, development and        commercialization milestones. In addition, Eleven could be entitled to        receive royalties based on net sales of potential future products        containing EBI-031 or any other potential future products containing        other Eleven IL-6 compounds. Viventia Acquisition Details
Under the share purchase agreement, Eleven purchased all of the        outstanding capital stock of Viventia in exchange for the issuance of        4,031,431 newly issued shares of Eleven common stock, which represented        approximately 19.9% of the voting power of Eleven as of immediately        prior to the issuance of such shares, and the agreement by Eleven to pay        to the selling shareholders certain post-closing contingent cash        payments upon the achievement of specified milestones and based upon net        sales related to Viventia’s lead product candidate, Vicinium. The acquisition was approved by the boards of directors of both        companies. Stifel, Nicolaus & Company, Incorporated acted as financial advisor and        Wilmer Cutler Pickering Hale and Dorr LLP is acting as legal advisor to        Eleven. Hogan Lovells US LLP acted as legal counsel to Viventia. Management and Organization
In connection with the acquisition, Eleven’s Board of Directors elected        Stephen Hurly and Leslie L. Dan, Viventia’s former Executive Chairman        and largest beneficial owner prior to the acquisition, to serve as        members of Eleven’s Board of Directors, and Cary G. Pfeffer, M.D.,        resigned from the Eleven’s Board of Directors. Stephen Hurly will serve        as President and Chief Executive Officer of Eleven. Also in connection        with the acquisition, Arthur P. DeCillis, M.D., Viventia’s Chief Medical        Officer, was appointed as Chief Medical Officer of Eleven, and Karen L.        Turbidy, Eleven’s Chief Development Officer, resigned from Eleven. In        addition, Gregory Adams Ph.D., Chief Development Officer and Glen        MacDonald, Ph.D., Chief Scientific Officer, will join Eleven’s        management team from Viventia. John McCabe, will continue to serve as        Chief Financial Officer of Eleven. Abbie C. Celniker, former President        and Chief Executive Officer of Eleven, will remain a member of Eleven’s        Board of Directors. Following the acquisition, an entity affiliated with        Leslie L. Dan became the second largest shareholder of Eleven. Conference Call and Webcast
Eleven Biotherapeutics and Viventia will host a conference call and        audio webcast today at 8:30 a.m. ET to discuss the acquisition. To        access the conference call, please dial (844) 831-3025 (domestic) or        (315) 625-6887 (international) at least five minutes prior to the start        time and refer to conference ID 85062695. An audio webcast of the call will also be available on the Investors & Media section of the Company’s website,  www.elevenbio.com . An archived webcast will be available on the Company’s website        approximately two hours after the event and will be available for 30        days. About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing        a broad pipeline of novel anti-cancer agents based on the Company’s        targeted protein therapeutics (TPTs) platform. The Company’s TPTs        genetically combine antibody-based fragments with protein immunotoxin        payloads to create a single protein molecule through the Company’s        proprietary one-step manufacturing process. The Company believes its        TPTs can potentially offer significant advantages in treating cancer        versus existing antibody drug conjugate technologies. The Company’s        approach to drug design creates TPTs that it believes facilitate        effective tumor targeting with cancer cell-killing properties unique to        protein payloads versus small molecules. The ability of TPTs cancer        cell-killing properties to promote an anti-tumor immune response suggest        that TPTs will potentially combine well with immune oncology drugs. TPTs        fusion protein construction provides enhanced linker stability and an        efficient and cost effective manufacturing process. For more information        please refer to the Company’s website www.elevenbio.com . About Non-Muscle Invasive Bladder Cancer (NMIBC)
In the U.S., NMIBC is the second most common malignancy of the        genitourinary system, accounting for 70% to 80% of all bladder cancers,        and is the sixth most common cancer diagnosed worldwide. The American        Cancer Society estimated that approximately 74,000 new cases of bladder        cancer were diagnosed in 2015 and that this cancer caused approximately        16,000 deaths in the US in 2015. NMIBC is highly recurrent and requires        ongoing, invasive monitoring. The standard immunotherapy drug for bladder cancer is the Bacillus        Calmette-Guérin (BCG) vaccine which was approved by the U.S. Food and        Drug Administration (FDA) to treat NMIBC carcinoma in situ in 1990. As a        front-line therapy, BCG, with or without transurethral resection of the        bladder tumor (TURBT) is associated with high failure rates: 50% of        patients experience disease recurrence within one year and 90% relapse        within five years. For more information please visit www.mybladdercancer.com . About Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Squamous cell carcinoma is the most frequent malignant tumor of the head        and neck region. Head and neck cancer is the seventh most common cancer        in the world. Head and neck cancers are strongly associated with certain        environmental and lifestyle risk factors. Existing treatment options for squamous cell carcinoma of the head and        neck include surgery, drug agents, radiation or combination therapy. There is no treatment option for patients who progress after receiving        these treatments. Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans        and prospects for the Company, including statements about benefits of        the Acquisition, future management of the Company, Viventia’s business,        the Company’s strategy, future operations, advancement or maturation of        its product candidates and product pipeline, clinical development of the        Company’s product candidates, including expectations regarding timing of        regulatory submissions and initiation of clinical trials, regulatory        requirements for initiation of clinical trials and registration of        product candidates, the sufficiency of its cash resources and other        statements containing the words “anticipate,” “believe,” “estimate,”        “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”        “potential,” “will,” “would,” “could,” “should,” “continue,” and similar        expressions, constitute forward-looking statements within the meaning of        The Private Securities Litigation Reform Act of 1995. Actual results may        differ materially from those indicated by such forward-looking        statements as a result of various important factors, including: the        uncertainties inherent in the initiation and conduct of clinical trials,        availability and timing of data from clinical trials, whether results of        early clinical trials or preclinical studies will be indicative of the        results of future trials, the adequacy of any clinical models,        uncertainties associated with regulatory review of clinical trials and        applications for marketing approvals and other factors discussed in the        “Risk Factors” section of the Company’s report on Form 10-Q for the        quarter ended June 30, 2016 as filed with the Securities and Exchange        Commission, the “Risk Factors of Viventia’s Business” filed as Exhibit        99.2 to the Company’s Current Report on Form 8-K filed with the        Securities and Exchange Commission on September 21, 2016 and other        reports on file with the Securities and Exchange Commission. In        addition, the forward-looking statements included in this press release        represent the Company’s views as of the date hereof. The Company        anticipates that subsequent events and developments will cause the        Company’s views to change. However, while the Company may elect to        update these forward-looking statements at some point in the future, the        Company specifically disclaims any obligation to do so. These        forward-looking statements should not be relied upon as representing the        Company’s views as of any date subsequent to the date hereof. View source version on businesswire.com: http://www.businesswire.com/news/home/20160921005462/en/

OncoSec Medical

GrowthWorks

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

Viventia, fka Novopharm Biotech, is a biopharmaceutical company that designs, develops, engineers, and commercializes protein therapeutic technology and advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer. Viventia is employing its monoclonal antibody discovery and development platforms to discover, validate, and advance a portfolio of new antibody products based on oncology drug targets.

Viventia

Sesen Bio

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.

TolerRx is discovering, developing, and seeking to commercialize therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases - diseases such as diabetes, psoriasis, lupus, and others - after a short course of therapy.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Kenta Biotech vs Viventia

Customers evaluate the quality of Kenta Biotech's products using the following success metrics.